Searchable abstracts of presentations at key conferences in endocrinology

ea0024p5 | (1) | BSPED2010

A 30 years review of congenital adrenal hyperplasia in Northern Ireland

Dixon J , Carson D

Background: Congenital adrenal hyperplasia (CAH) is an autosomal recessive condition with significant consequences if not correctly diagnosed and treated. We have reviewed the patients with CAH presenting in Northern Ireland between 1976 and 2010.Aims: To determine the age, sex and clinical features at presentation; treatment modalities including perineal surgery in childhood; and long-term outcomes including final height and surgery in adulthood.<p ...

ea0024p58 | (1) | BSPED2010

Persistent hypernatremia in infants…think diabetes insipidus

Iyer D , Karandikar S

Introduction: Central diabetes insipidus (CDI) in infants is rare and is often associated with intra-ventricular haemorrhage, congenital toxoplasmosis, intracranial tumours and anatomical abnormalities of the brain. We describe two cases of CDI associated with brain malformations, diagnosed at very young age with good response to oral DDAVP.Case 1: A 34-week IUGR girl born to consanguineous parents (first cousins) developed hypernatraemia on day three of...

ea0022s2.2 | Endocrine aspects about the metabolic syndrome | ECE2010

Combined GH and IGF1 therapy

Dunger D B

Epidemiological studies indicate that low circulating concentrations of IGF1 are associated with increased adult risk for the development of type 2 diabetes (T2D) and the metabolic syndrome (MS). Although comparable epidemiological data relating to GH concentrations are lacking, GH deficiency (GHD) is associated with many of the features of the MS and increased T2D risk. These data indicate that reduced activity of the GH/IGF1 axis is a risk factor for MS yet IGF1 and GH have ...

ea0019p313 | Steroids | SFEBES2009

Dehydroepiandrosterone steroids are regulators of immune function via leukocyte annexin 1

Renshaw D , Flower R

There is evidence from human studies that dehydroepiandrosterone (DHEA) may regulate acquired immunity by promoting a shift towards a T helper type 1 (Th1) phenotype and in innate immunity by suppression of inflammation. Interestingly, circulating levels of DHEA/DHEA-S are significantly reduced in patients with rheumatoid arthritis and systemic lupus erythematosis and are also negatively correlated with age.Annexin 1 (ANXA1) is a glucocorticoid-induced p...

ea0019p336 | Steroids | SFEBES2009

1,25-dihydroxyvitamin D3 increases the expression of intercellular adhesion molecule-1 (ICAM-1) and interleukin 8 (IL-8) in a human proximal tubule cell line

Markovic D , Bland R

The active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25D3), is a potent regulator of the immune system and activation of the vitamin D receptor alters expression and secretion of cytokines, chemokines and cell adhesion factors. Initial studies suggested that 1,25D3 synthesis and metabolism are increased in renal epithelial cells by TNFα and IL-1β. Therefore, the aim of this study was to examine whether vitamin D alters the expression of immune activated molecule...

ea0013s9 | Transdifferentiation in the endocrine system | SFEBES2007

Fibroblasts and tissue remodelling: Defining a role for fibroblasts in the persistence of chronic inflammation

Buckley Christopher D

One of the most important but as yet unanswered questions in inflammation research is not why chronic inflammation occurs but why is does not resolve. Current models of inflammation stress the role of antigen-specific lymphocyte responses and attempt to address the causative agent. However recent studies have begun to challenge the primacy of the lymphocyte and have begun to focus on an extended immune system in which stromal cells, such as macrophages and fibroblasts play a r...

ea0013p27 | Clinical practice/governance and case reports | SFEBES2007

Familial hypoparathyroidism- case notes review and relevance to clinical practice

Maguire D , Peacey SR

Familial hypoparathyroidism is a rare condition. A family with seven affected individuals is described. Six sets of case notes were available for comparison. The most probable type of genetic transmission is autosomal dominant. There is also a family history of renal stones and ankylosing spondylitis.At diagnosis, adjusted calcium levels ranged between 1.77 and 1.92 mmol/L. PTH levels were either undetectable or in the low-normal range. Most cases were s...

ea0013p342 | Thyroid | SFEBES2007

Hyperemesis gravidarum and gestational hyperthyroidism

Maguire D , Whitelaw DC

Hyperemesis gravidarum is vomiting in pregnancy severe enough to cause weight loss and hospitalization. It occurs in up to 1% of pregnancies. It usually begins at 6–9 weeks gestation and resolves by 18–20 weeks. It can lead to dehydration and electrolyte imbalances. Treatment includes intravenous fluids and anti-emetics. The cause of vomiting is unknown. Hyperemesis gravidarum is often associated with transient gestational hyperthyroidism.The a...

ea0012p30 | Clinical case reports/Governance | SFE2006

A case of Gitelman’s syndrome, a variant of Bartter’s syndrome

Arefin AN , Nagi D

A 22-year old lady was referred with a history of fatigue, generalised aches and pains. Investigations revealed persistently low potassium on few occasions. There was no history of diarrhoea or vomiting. No laxative, diuretic or liquorice abuse. PMH: treated hypothyroidism and Idiopathic thrombocytopenic purpura. She weighed 46 kg and her BP was 115/63. Further investigations: sodium 140 mmol/l, potassium 2.6 mmol/l (3.5–5.0), bicarbonate 28 mmol/l (22–28), magnesium...

ea0012p64 | Endocrine tumours and neoplasia | SFE2006

A probable PTH- secreting metastatic breast carcinoma

Kar P , Meeking D

A 50-year-old woman was admitted to hospital feeling unwell.Biochemistry: Calcium 3.46 (2.15–2.6),PO4 0.42 (0.8–1.5), AlkalinePhosphatase 259 (30–95). She had been diagnosed 3 years ago with Carcinoma breast and had undergone surgery,chemotherapy and radiotherapy. Regular follow-up had not shown any recurrence.No breast lump or bony tenderness was recorded.Further biochemistry: PTH 30 (0–6...